AMRI inks deal with Biota Holdings
AMRI was recently selected by Biota Holdings Ltd. to further develop and manufacture the influenza antiviral CS8958 (laninamivir), a second-generation, long-acting neuraminidase inhibitor
To continue reading this article, subscribe for FREE to
Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.
Related Topics
Published In
Volume 8 - Issue 6 | June 2012
June 2012
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Can animal testing be replaced? Discover how scientists are developing more human-relevant ways to predict drug toxicity earlier.
Learn about common challenges and proper maintenance practices for catheterized rodent models.
Learn why data quality, governance, and collaboration are critical to realizing AI’s potential across the drug discovery pipeline.
